<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205734</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00028947</org_study_id>
    <nct_id>NCT04205734</nct_id>
  </id_info>
  <brief_title>Methotrexate Polyglutamate Measurements in Patients With Inflammatory Bowel Disease</brief_title>
  <official_title>Methotrexate Polyglutamate Measurements in Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are currently no serum levels to help guide appropriate methotrexate therapy. Data from
      this study will assess the correlation between dosing and whole blood methotrexate(MTX)
      polyglutamate measurements in children and adolescents with IBD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-sectional study design. Subjects will be requested to provide one blood
      sample to be collected during the conduct of their routine clinical care. Data related to the
      diagnosis and interval assessment of enrolled subjects will also be collected.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Methotrexate Polyglutamate Level</measure>
    <time_frame>Samples will collected within 16 weeks of consent.</time_frame>
    <description>Measurement of Methotrexate Polyglutamate Levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The correlation between Methotrexate Polyglutamate Levels and Lab Parameters</measure>
    <time_frame>Samples will collected within 16 weeks of consent.</time_frame>
    <description>Compare the relationship between Methotrexate Polyglutamage levels and ESR,CRP, Hemoglobin, and Albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between Methotrexate Polyglutamate Levels and Clinical History</measure>
    <time_frame>Samples will collected within 16 weeks of consent.</time_frame>
    <description>Do Methotrexate Polyglutamate Levels Predict Clinical Outcome as Measured by Disease Activity Indices, including PUCAI for ulcerative colitis and PCDAI for patients with Crohn Disease</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>IBD</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MTX Assessment</intervention_name>
    <description>Measurement of Methotrexate Polyglutamate levels.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5 ml of whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with IBD being treated with methotrexate (oral or subcutaneous)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBD

          -  Methotrexate Therapy

        Exclusion Criteria:

          -  Inability to provide relevant samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Paul Rufo</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

